Login to Your Account



With DN-101 In Phase II/III Trial, Novacea Closes $36M Series B

By Brady Huggett


Tuesday, November 5, 2002
Novacea Inc. pulled in $36 million in its Series B round of financing, a sum the company says is validated by its drug in a later-stage trial and a solid group at the top. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription